<DOC>
	<DOCNO>NCT00571467</DOCNO>
	<brief_summary>The primary purpose study evaluate safety multiple dose Staphylococcal protein A ( PRTX-100 ) adult patient Idiopathic Thrombocytopenia Purpura ( ITP ) . The pharmacokinetics , immunogenicity pharmacodynamics also study . Patients enrol 1 3 dose group receive 4 weekly IV dose PRTX-100 . A Safety Monitoring Committee review safety data Day 28 first 5 patient dose group escalation next high dose level . Patients follow 8 week dose safety , PK , immunogenicity effect platelet count ( pharmacodynamics ) .</brief_summary>
	<brief_title>Phase I Safety Tolerability Study Staphylococcal Protein A Adult Patients With Chronic ITP</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Diagnosis chronic ITP &gt; 4 month Mean platelet count &lt; 50 x 10^9/L patient receive corticosteroid ; mean platelet count &gt; =50 x 10^9/L patient receive stable dose corticosteroid Splenectomy within 45 day screen Rituximab within 6 month prior screen Cyclophosphamide , vincristine , nonmonoclonal antibody treatment ITP within 3 month prior screen IVIG , WinRho antiRhD within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Bleeding Disorders</keyword>
	<keyword>Blood Blood Disorders</keyword>
</DOC>